NCI-H209
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
NCI-H209 |
Humane Lungenkarzinom (kleinzellig) Zell-Linie |
300183 |
cryovial |
265,00 |
NCI-H209 |
Humane Lungenkarzinom (kleinzellig) Zell-Linie |
330183 |
vital |
335,00 |
| Designation: | NCI-H209 |
| Depositor: | Minna |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Gender: | male |
| Tissue: | lung; from metastatic Site: bone marrow |
| Morphology: | epithelial |
| Celltype: | small cell lung carcinoma |
| Growth Properties: | Aggregates in suspension |
| Description: | The NCI-H209 cell line was derived by A.F. Gazdar and associates in 1979 from the bone marrow of a patient with small cell cancer of the lung. The bone marrow specimen was taken prior to therapy. The line is a classic SCLC cell line which expresses elevated levels of four biochemical markers (neuron specific enolase, brain isoenzyme of creatine kinase, L-DOPA decarboxylase and bombesin-like immunoreactivity. C-myc DNA sequences are not amplified. No gross structural DNA abnormalities were detected. The line produces normal amounts of p53 mRNA relative to normal lung. This is a cell line that grows as large aggregates in suspension. Only the aggregates are viable, but no meaningful viability percentage can be measured. The medium will normally contain large amounts of cell debris. The cells express an aberrant form of RB1 that is not phosphorylated, apparently due to a single point mutation at codon 706 (Cys -> Phe). |
| Culture Medium: | Iscove's modified Dulbecco's medium supplemented with 2 mM L-glutamine and 10% fetal bovine serum. Alternatively, RPMI 1640 medium supplemented with 2 mM L-glutamine and 10-20% fetal bovine serum may be used. |
| Subculturing: | The line should be subcultured by dilution with fresh medium. Alternatively, the clusters may be collected by centrifugation and resuspended in fresh medium. |
| Split Ratio: | A ratio of 1:2 to 1:3 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes; forms transplantable tumors with typical SCLC histology in nude mice |
| Oncogene: | pRB (RB1, abnormal) |
| Karyotype: | This is a hyperdiploid human cell line. The modal chromosome number is 49, occurring at 28% with a frequency of higher ploidies of 1.3%. Ten to eleven markers were common to all cells including: der(1)t(1;3)(p22;p21), del(6)(q21), t(8q18q), del(12)(q13), der(14)t(14;?)(q32;?). All had a single copy per cell. About 6 other markers were found, but they occurred only once in all metaphases karyotyped. Neither HSR nor DM were detected. Structurally normal B group chromosomes were not detected. All C group chromosomes were paired. A single copy of both the X and Y was found in all cells. |
| Isoenzymes: | G6PD, B; PGM1, 1-2; PGM3, 1; ES-D, 1; Me-2, 0; AK-1, 1; GLO-1, 1-2; Phenotype Frequency Product = 0.0624 |
References: Moody TW et al. Bombesin-like peptides in small cell lung cancer: biochemical characterization and secretion from a cell line. Life Sci 32: 487-93, 1983. Little CD et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. Carney DN et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. Curt GA et al. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin Invest 76: 1323-9, 1985 Korman LY et al. Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung. Cancer Res 46: 1214-8, 1986. Yoder DG et al. High affinity binding of cholecystokinin to small cell lung cancer cells. Peptides 8: 103-7, 1987. Allen AE et al. Neurotensin binds with high affinity to small cell lung cancer cells. Peptides 9 Suppl 1: 57-61, 1988. Nakanishi Y et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 82: 354-9, 1988. Takahashi T et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. Marley GM et al. Potentation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancercell lines. Cancer Res 49: 6232-6, 1989. Hensel CH et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. Kaye FJ et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926, 1990. Cairns P et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. Rostomily RC et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. Renaudo A et al. Inhibition of tumor cell proliferation by sigma ligands is associated with K+ Channel inhibition and p27kip1 accumulation. J Pharmacol Exp Ther 311: 1105-14, 2004. Tanno S et al. Small cell lung cancer cdells express EGFR and tyrosine phosphorylation of EGFR is inhibited by geftinib (“Iressa”, ZD1839). Oncol Rep 12: 1053-7, 2004. Grigorova M et al. Chromosome abnormalities in 10 lung cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet 162: 1-9, 2005. Yang JH et al. Inhibition of lung cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab Dispos 34: 296-304, 2006. Li B et al. Involvement of Rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett 580: 4252-60, 2006. | |
